Business
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million an
About this update from Coherus Oncology, Inc.
[{"type":"image","alt":"Coherus BioSciences, Inc.","displaySize":"","headline":null,"caption":"Coherus BioSciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/d87de5d193580fe10b8b8dc96f150ded"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2xBqfzNhYYlTu.OjLDmoUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d87de5d193580fe10b8b8dc96f150ded","width":300,"height":75}},"lazy":false},{"type":"text","content":"– Strategic transformation to innovative oncology completed in Q2 2025 –","length":72,"tagName":"p"},{"type":"text","content":"– Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – ","length":236,"tagName":"p"},{"type":"text","content":"– Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 –","length":149,"tagName":"p"},{"type":"text","content":"– LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025 –","length":143,"tagName":"p"},{"type":"text","content":"– Conference call today at 5:00 p.m. Eastern Time –","length":51,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2025 and provided an overview of recent business highlights.","length":246,"tagName":"p"},{"type":"text","content":"“The completion of the UDENYCA divestiture in April positions us to focus on our innovative oncology portfolio,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “This includes maximizing LOQTORZI revenues, advancing our novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026, and progressing label expanding indications for LOQTORZI in novel combinations. The commercial launch of LOQTORZI continues to progress with patient demand growing more than 15% in the first quarter of 2025 versus the fourth quarter of last year.”","length":579,"tagNa...